GlassScriptPhysician profile
Amy L Swerczek
NPI 1093002255
$2,437.34
in general payments reported to CMS, 2019-2025
25 companies · $86.33 in 2025
The $86.33 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $204 · 2022: $641 · 2023: $719 · 2024: $787 · 2025: $86.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $738.89 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Amgen INC. | $217.44 | 2021-2024 | Tezspire |
| Jazz Pharmaceuticals INC. | $201.70 | 2021-2024 | |
| Electromed, INC. | $173.22 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.78 | 2021-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Harmony Biosciences LLC | $123.56 | 2022-2024 | Wakix |
| Grifols USA, LLC | $109.53 | 2021-2024 | Prolastin-C Liquid |
| United Therapeutics Corporation | $101.01 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $96.26 | 2022-2024 | Uptravi, Opsumit |
| Baxter Healthcare | $79.57 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Pulmonx Corporation | $69.19 | 2022-2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Genzyme Corporation | $47.44 | 2022-2024 | |
| Insmed, INC. | $42.93 | 2021-2025 | Arikayce |
| Glaxosmithkline, LLC. | $38.68 | 2022-2025 | Nucala |
| Mallinckrodt Hospital Products INC. | $34.34 | 2023 | Acthar |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $33.87 | 2022-2023 | |
| Verona Pharma, INC. | $29.98 | 2025 | Ohtuvayre |
| Avadel Cns Pharmaceuticals, LLC | $29.19 | 2024 | Lumryz |
| Regeneron Healthcare Solutions, INC. | $27.08 | 2021-2023 | Dupixent |
| Pharming Healthcare, INC. | $21.09 | 2022 | |
| Mylan Specialty L.P. | $19.58 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.89 | 2023 | Glassia |
| Nabriva Therapeutics, Plc | $16.41 | 2022 | |
| Axsome Therapeutics, INC. | $15.23 | 2024 | Sunosi |
| Janssen Pharmaceuticals, INC | $13.48 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Swerczek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.